



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/663,872

09/16/2003

Liliana Tejidor

00825Div.JAR

3114

7590
Judith A. Roesler, Esq.
BioMerieux, Inc.
Patent Department
100 Rodolphe Street
Durham, NC 27712

02/06/2007

EXAMINER

CHEU, CHANGHWA J

ART UNIT

PAPER NUMBER

1641

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

02/06/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

10/663.872

EXAMINER

J. Chen

ART UNIT

PAPER

20070131

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The amendment filed on 11/20/2006 changed the kit (claims 101-105) assessing the hemostatic potential of a test sample to a kit (claims 106-110) used for screening or drug discovery of a patient treated with inhibitors of tissue factor pathway, thrombin generation or thrombin activity is non-responsive (MPEP § 821.03).

Both set of claims are patentably distinct since the feature of "differentiating hyper, normal and hypocoagulable plasma" in claims 101-105, is not required by claims 106-110. Likewise, the feature of having treated with inhibitors in a patient is not required by the claims 101-105. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits.

See 37 CFR 1.142 (b) and MPEP section 821.03. Since the above-mentioned amendment appears to be a bona fide attempt to reply, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, whichever is longer, from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD UNDER 37 CFR 1.136(a) ARE AVAILABLE.

Long V. Le
LONG V. LE 02/02/07
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1800